Germany· DE-A57-b0da8a70afcd444d
Rande
A ranolazine product containing ranolazine, registered in Germany by Day Zero Ehf. The same ATC class is registered in 16 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Ranolazine is registered in 16 of 19 countries.
Countries holding a registration under ATC C01EB18 (ranolazine), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 10 of them publish a price we can compare per daily dose
Ranolazine · ATC C01EB18
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ranolazine costs, country by country.
Normalised to the WHO defined daily dose (1.5 g), the median price runs from $0.49 in United States to $5.07 in Switzerland — a ×10 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Ranolazine · price per daily dose (1.5 g)
USD · FX 28 Sept 2026
- CH Switzerland$5.07
- ES Spain$1.58
- IT Italy$0.87
- US United States$0.49 (acquisition cost)
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Ranolazine
- Manufacturer
- Day Zero Ehf
- Country
- Germany (DE)
- ATC code
- C01EB18
- ATC class
- Ranolazine
- Defined daily dose
- 1.5 g, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
335 interactions on record for ranolazine.
Graded by severity as the source publishes them — 78 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ranolazine · interactions on record
335 records
- 78 severe
- 205 moderate
- 29 minor
- 23 info
Most severe, free to view
- ClotrimazoleA01AB18severe
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under C01EB18
Ranolazine, as other registers publish it.
- United KingdomAnzipro 375mg modified-release tabletsRidge Pharma Ltd
- United KingdomAnzipro 500mg modified-release tabletsRidge Pharma Ltd
- United KingdomAnzipro 750mg modified-release tabletsRidge Pharma Ltd
- United StatesASPRUZYO SPRINKLESUN PHARMACEUTICAL INDUSTRIES, INC.
- CanadaCORZYNAKYE PHARMACEUTICALS INC.
- CanadaCORZYNAKYE PHARMACEUTICALS INC.
- GermanyHalibrellHexal Ag
- DenmarkLabigatPharmathen S.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/984ab235-9750-4746-ab1d-26cb2090037a GET /v1/drugs/984ab235-9750-4746-ab1d-26cb2090037a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Ranolazine",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about ranolazine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.